The Bio/Pharma Beat

    View Author February 2020

    We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from January 2020, including:

    • The Federal Circuit holds that post-priority evidence can be used to show inherency in the obviousness context
    • The Federal Circuit explains that enablement of an allegedly anticipatory reference does not necessarily equate to anticipation and the two concepts should not be confused
    • A district court holds, in a drug/prodrug case, that the enforceable rights derived from a patent term extension are limited to the approved uses of the approved active ingredient